ABL1 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ABL1 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ALK is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains ALK status and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

ARID1A is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ARID1A status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ATM is an inclusion eligibility criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain ATM status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

ATR is an inclusion eligibility criterion in 4 clinical trials for gastric carcinoma, of which 3 are open and 1 is closed. Of the trials that contain ATR status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [3].

ATRX is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ATRX status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

BACH1 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains BACH1 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

BARD1 is an inclusion eligibility criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain BARD1 status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

BRAF is an inclusion eligibility criterion in 5 clinical trials for gastric carcinoma, of which 3 are open and 2 are closed. Of the trials that contain BRAF status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 3 are phase 2 (2 open) [3].

BRCA1 is an inclusion eligibility criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain BRCA1 status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

BRCA2 is an inclusion eligibility criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain BRCA2 status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

BRIP1 is an inclusion eligibility criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain BRIP1 status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

C11orf30 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains C11orf30 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

CCND1 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND1 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

CCND2 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND2 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

CCND3 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCND3 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

CCNE1 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCNE1 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

CCNE2 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CCNE2 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

CD274 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains CD274 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

CDK12 is an inclusion eligibility criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain CDK12 status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

CDK2 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDK2 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

CDK4 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDK4 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

CDK6 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDK6 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

CDKN1A is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1A status and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

CDKN1B is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN1B status and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

CDKN2A is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains CDKN2A status and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

CHEK1 is an inclusion eligibility criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain CHEK1 status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

CHEK2 is an inclusion eligibility criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain CHEK2 status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

DDR2 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains DDR2 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

EGFR is an inclusion eligibility criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain EGFR status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (2 open) [3].

EPHA2 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains EPHA2 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERBB2 is an inclusion eligibility criterion in 29 clinical trials for gastric carcinoma, of which 13 are open and 16 are closed. Of the trials that contain ERBB2 status and gastric carcinoma as inclusion criteria, 13 are phase 1 (4 open), 5 are phase 1/phase 2 (4 open), 8 are phase 2 (4 open), 1 is phase 2/phase 3 (0 open), and 2 are phase 3 (1 open) [3].

Capecitabine, cisplatin, trastuzumab, and fluorouracil have evidence of efficacy in patients with ERBB2 mutation in gastric carcinoma [3].

ERBB3 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB3 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

ERBB4 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERBB4 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

ERCC2 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC2 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ERCC3 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC3 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ERCC4 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC4 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ERCC5 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC5 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

ERCC6 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains ERCC6 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

FANCA is an inclusion eligibility criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain FANCA status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

FANCB is an inclusion eligibility criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain FANCB status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

FANCC is an inclusion eligibility criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain FANCC status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

FANCD2 is an inclusion eligibility criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain FANCD2 status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

FANCE is an inclusion eligibility criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain FANCE status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

FANCF is an inclusion eligibility criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain FANCF status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

FANCG is an inclusion eligibility criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain FANCG status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

FANCI is an inclusion eligibility criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain FANCI status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

FANCL is an inclusion eligibility criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain FANCL status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

FANCM is an inclusion eligibility criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain FANCM status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

FGF1 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF1 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF10 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF10 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF11 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF11 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF12 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF12 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF13 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF13 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF14 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF14 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF16 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF16 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF17 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF17 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF18 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF18 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF19 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF19 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF2 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF2 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF20 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF20 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF21 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF21 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF22 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF22 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF23 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF23 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF3 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF3 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF4 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF4 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF5 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF5 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF6 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF6 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF7 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF7 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF8 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF8 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGF9 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FGF9 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

FGFR1 is an inclusion eligibility criterion in 5 clinical trials for gastric carcinoma, of which 5 are open and 0 are closed. Of the trials that contain FGFR1 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 3 are phase 2 (3 open) [3].

FGFR2 is an inclusion eligibility criterion in 6 clinical trials for gastric carcinoma, of which 5 are open and 1 is closed. Of the trials that contain FGFR2 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (3 open) [3].

FGFR3 is an inclusion eligibility criterion in 3 clinical trials for gastric carcinoma, of which 3 are open and 0 are closed. Of the trials that contain FGFR3 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [3].

FGFR4 is an inclusion eligibility criterion in 2 clinical trials for gastric carcinoma, of which 2 are open and 0 are closed. Of the trials that contain FGFR4 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [3].

FLT1 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT1 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FLT4 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FLT4 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

FRK is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains FRK status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

HDAC1 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HDAC1 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

HDAC2 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HDAC2 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

HRAS is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains HRAS status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

IDH1 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains IDH1 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

IDH2 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains IDH2 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KDR is an inclusion eligibility criterion in 2 clinical trials for gastric carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KDR status and gastric carcinoma as inclusion criteria, 2 are phase 2 (1 open) [3].

KIT is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KIT status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

KRAS is an inclusion eligibility criterion in 3 clinical trials for gastric carcinoma, of which 2 are open and 1 is closed. Of the trials that contain KRAS status and gastric carcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (0 open) [3].

MAP2K1 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K1 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K2 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K2 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K3 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K3 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K4 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K4 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K5 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K5 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K6 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K6 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAP2K7 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAP2K7 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAPK1 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK1 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MAPK11 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK11 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

MAPK3 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MAPK3 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MCPH1 is an inclusion eligibility criterion in 3 clinical trials for gastric carcinoma, of which 2 are open and 1 is closed. Of the trials that contain MCPH1 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 2 are phase 1/phase 2 (2 open) [3].

MDM2 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDM2 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MDM4 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MDM4 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MET is an inclusion eligibility criterion in 4 clinical trials for gastric carcinoma, of which 2 are open and 2 are closed. Of the trials that contain MET status and gastric carcinoma as inclusion criteria, 3 are phase 1 (2 open) and 1 is phase 2 (0 open) [3].

MLF1 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLF1 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MLH1 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH1 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MLH3 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MLH3 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MRE11A is an inclusion eligibility criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain MRE11A status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

MSH2 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH2 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MSH3 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH3 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MSH6 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MSH6 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

MUTYH is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains MUTYH status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

NBN is an inclusion eligibility criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain NBN status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

NPM1 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NPM1 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

NRAS is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains NRAS status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PALB2 is an inclusion eligibility criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain PALB2 status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

PARP1 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP1 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PARP2 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PARP2 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PDGFRB is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PDGFRB status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

PIK3CB is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PIK3CB status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

PMS1 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS1 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PMS2 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PMS2 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

POLD1 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLD1 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

POLD2 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains POLD2 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

POLE is an inclusion eligibility criterion in 2 clinical trials for gastric carcinoma, of which 2 are open and 0 are closed. Of the trials that contain POLE status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [3].

PPP2R1A is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PPP2R1A status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PPP2R2A is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains PPP2R2A status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

PTEN is an inclusion eligibility criterion in 4 clinical trials for gastric carcinoma, of which 3 are open and 1 is closed. Of the trials that contain PTEN status and gastric carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 3 are phase 1/phase 2 (3 open) [3].

RAD50 is an inclusion eligibility criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain RAD50 status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

RAD51 is an inclusion eligibility criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain RAD51 status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

RAD51B is an inclusion eligibility criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain RAD51B status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

RAD51C is an inclusion eligibility criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain RAD51C status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

RAD51D is an inclusion eligibility criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain RAD51D status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

RAD54L is an inclusion eligibility criterion in 5 clinical trials for gastric carcinoma, of which 4 are open and 1 is closed. Of the trials that contain RAD54L status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open), 2 are phase 1/phase 2 (2 open), and 1 is phase 2 (1 open) [3].

RAF1 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RAF1 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RB1 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RB1 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

RET is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains RET status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

RICTOR is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 0 are open and 1 is closed. Of the trial that contains RICTOR status and gastric carcinoma as inclusion criteria, 1 is phase 2 (0 open) [3].

SLX4 is an inclusion eligibility criterion in 4 clinical trials for gastric carcinoma, of which 3 are open and 1 is closed. Of the trials that contain SLX4 status and gastric carcinoma as inclusion criteria, 2 are phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [3].

SMARCB1 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains SMARCB1 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

STAG2 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains STAG2 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

STK11 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains STK11 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].

TEK is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TEK status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

TNFRSF10B is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TNFRSF10B status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TP53 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TP53 status and gastric carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [3].

TRNAK2 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains TRNAK2 status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFA is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFA status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFB is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFB status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

VEGFC is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains VEGFC status and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [3].

XRCC1 is an inclusion eligibility criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains XRCC1 status and gastric carcinoma as inclusion criteria, 1 is phase 1 (1 open) [3].